Boyle Scott N (CIK 1913897) reported 10 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-02-18). Recent activity: Buy CCCC (200,000 shares), Buy CCCC (5,000 shares), Sell CCCC (1,735 shares), Buy CCCC (20,950 shares), Sell CCCC (7,269 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-18 | C4 Therapeutics, Inc. (CCCC) | Chief Business Officer | Buy | 200,000 | $0 |
| 2026-02-18 | C4 Therapeutics, Inc. (CCCC) | Chief Business Officer | Buy | 5,000 | $0 |
| 2026-02-18 | C4 Therapeutics, Inc. (CCCC) | Chief Business Officer | Sell | 1,735 | $3,279 |
| 2026-02-18 | C4 Therapeutics, Inc. (CCCC) | Chief Business Officer | Buy | 20,950 | $0 |
| 2026-02-18 | C4 Therapeutics, Inc. (CCCC) | Chief Business Officer | Sell | 7,269 | $13,738 |
| 2025-02-18 | C4 Therapeutics, Inc. (CCCC) | Chief Business Officer | Sell | 1,735 | $5,552 |
| 2025-02-18 | C4 Therapeutics, Inc. (CCCC) | Chief Business Officer | Buy | 56,500 | $0 |
| 2025-02-18 | C4 Therapeutics, Inc. (CCCC) | Chief Business Officer | Sell | 490 | $1,544 |
| 2025-02-18 | C4 Therapeutics, Inc. (CCCC) | Chief Business Officer | Sell | 2,368 | $7,530 |
| 2025-02-18 | C4 Therapeutics, Inc. (CCCC) | Chief Business Officer | Sell | 669 | $2,107 |
Source: SEC Form 4 filings · as of 2026-02-18